Abstract
Abstract 1723 Background: Two multicenter studies (MDS-003/-004) found LEN leads to RBC transfusion independence (TI) in > 50% of pts with RBC transfusion dependent Low-/Int-1-risk MDS with del5q (List A et al. NEJM 2006;355: 1456–65; Fenaux P et al. Blood 2011;doi: 10.1182/blood-2011-01-330126). RBC-TI ≥ 8 wks with LEN was associated with significantly reduced risk of AML progression and death (Fenaux P et al. Blood 2011;doi: 10.1182/blood-2011-01-330126). Alternative therapy is required for pts failing LEN therapy. Aims: To assess predictive factors of LEN response and long term outcomes (especially after primary or secondary LEN failure) of pts Methods: LEN was administered as follows (all 28-d cycles): 5 mg/d on d 1–28 and 10 mg/d on d 1–21 or 1–28. RBC-TI ≥ 26 wks and cytogenetic response (CyR; IWG 2000) are reported. Overall survival (OS) and AML progression were assessed using Kaplan-Meier method. Response rates and outcomes in pts Results: The trials included 97 (33.9%) pts Conclusions: LEN-treated pts Disclosures: Fenaux: Celgene Corporation: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Johnson & Johnson: Honoraria; Merck: Honoraria; Cephalon: Honoraria; Novartis: Honoraria. Giagounidis: Celgene Corporation: Consultancy, Honoraria, Membership on an entity9s Board of Directors or advisory committees. List: Celgene Corporation: Consultancy, Honoraria, Research Funding. Hellstrom-Lindberg: Celgene Corporation: Membership on an entity9s Board of Directors or advisory committees, Research Funding. Yu: Celgene Corporation: Employment, Equity Ownership. Skikne: Celgene Corporation: Employment. Shammo: Celgene Corporation: Honoraria, Research Funding, Speakers Bureau. del Canizo: Celgene Corporation: Spanish advisory committee.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have